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ABSTRACT
Castration-resistant prostate cancer (CRPC) expresses high levels of the anti-
apoptotic proteins Bcl-2, Bcl-xL and Mcl-1, resulting in resistance to apoptosis
and association with poor prognosis. Docetaxel, an antimitotic drug that is the
ﬁrst-line treatment strategy for CRPC, is known to provide a small survival beneﬁt.
However, docetaxel chemotherapy alone is not enough to counteract the high levels
of Bcl-2/Bcl-xL/Mcl-1 present in CRPC. ABT-737 is a small molecule that binds to
Bcl-2/Bcl-xL (but not Mcl-1) with high aYnity and disrupts their interaction with
pro-apoptoticBax/Bak,thusenhancingapoptosis.OurresultsindicatethatABT-737
can sensitize androgen-dependent LNCaP and CRPC PC3 cells to docetaxel- and to
the novel antimitotic ENMD-1198-mediated caspase-dependent apoptosis. CRPC
DU145 cells, however, are more resistant to ABT-737 because they are Bax null and
not because they express the highest levels of anti-apoptotic Mcl-1 (associated with
ABT-737 resistance). Knockdown of Bax or Bak in LNCaP indicates that ABT-737-
induced antimitotic enhancement of apoptosis is more dependent on the levels of
Bax than Bak. Furthermore, we ﬁnd that the ability of docetaxel to increase cyclin
B1/Cdk1-mediated phosphorylation of Bcl-2/Bcl-xL and decrease Mcl-1 is required
for ABT-737 to enhance apoptosis in PC3 cells, as determined by addition of Cdk1
inhibitor purvalanol A and expression of shRNA speciﬁc for cyclin B1. Overall,
our data suggests that the high levels of anti-apoptotic proteins in Bax-expressing
CRPCcellscanbeovercomebytargetingBcl-2/Bcl-xLwithABT-737andMcl-1with
antimitotics.
Subjects Molecular Biology, Oncology
Keywords Apoptosis, Antimitotic, ABT-737, Bcl-2 family, Cyclin B1/Cdk1
INTRODUCTION
Prostate cancer (PCa) is a leading cause of cancer-related death in men and remains
incurable in the metastatic setting. Despite the initial response to androgen deprivation,
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Gleave, 2007; Attar, Takimoto & Gottardis, 2009). Docetaxel (Doc) is an FDA approved
ﬁrst-line treatment for patients with CRPC but confers only a small survival beneﬁt
(Tannock et al., 2004). Once CRPC patients fail Doc chemotherapy, only the Doc
derivative cabazitaxel confers a slightly longer overall survival (de Bono et al., 2010). To
further improve overall survival of CRPC patients, a better mechanistic understanding
of Doc-induced CRPC cell death is required to develop more eVective combinatorial
treatments.
The anti-proliferative activity of Doc results from its ability to bind microtubules and
disrupt mitosis (Jordan & Wilson, 2004). Doc activates the mitotic checkpoint and blocks
the degradation of cyclin B1, leading to a prolonged activation of cyclin-dependant kinase
1 (Cdk1) and increased mitotic arrest, followed by induction of mitotic catastrophe or
apoptosis and also lysosome-dependent cell death (Castedo et al., 2004; Mediavilla-Varela
etal.,2009).WehavepreviouslyshownthatsmallmoleculeinhibitorsofCdk1canprevent
Doc-mediated increase in cyclin B1/Cdk1 activity and block induction of apoptosis in
CRPC cells (Perez-Stable, 2006; Gomez, de las Pozas & Perez-Stable, 2006). This ﬁnding
indicates that prolonged cyclin B1/Cdk1 activity phosphorylates apoptotic signaling
targets that can subsequently lead to apoptosis, although the precise mechanisms have
been diYcult to determine. However, it is likely that the mechanism involves substrates
phosphorylatedbycyclinB1/Cdk1.
ThemitoticresponsetoDocshowslittlevariationbetweencelltypes,whereastheability
to subsequently undergo apoptosis shows large variations (Shi, Orth & Mitchison, 2008;
Gascoigne & Taylor, 2008). This suggests that sensitivity to Doc depends to a greater extent
oncelltype-speciﬁcapoptoticsignalingmechanismsratherthanonpathwaysthatmediate
mitoticarrest.Bcl-2,Bcl-xL,andMcl-1areanti-apoptoticproteinsoftheBcl-2familythat
are highly expressed in CRPC, resulting in resistance to apoptosis and association with
poorprognosis(Karnak&Xu,2010).Bcl-2,Bcl-xL,andMcl-1protectcellsfromapoptosis
bybindingtoBaxandBak,pro-apoptoticmembersoftheBcl-2family,therebypreventing
theirhomodimerization.BaxandBakhomodimerspromoteapoptosisbyformingporesin
the mitochondria,leading to mitochondrial outermembrane permeabilization (MOMP),
cytochromecrelease,andtheactivationofthecaspasecascade(Chipuketal.,2010).
Interestingly, microtubule inhibitors such as Doc induce Bcl-2 and Bcl-xL phospho-
rylation, thus antagonizing their anti-apoptotic function (Haldar, Jena & Croce, 1995;
Poruchynskyetal.,1998).Furthermore,phospho-defectiveBcl-2andBcl-xLmutantsblock
the pro-apoptotic eVects of microtubule inhibitors, reinforcing the notion that mitotic
phosphorylation of Bcl-2 and Bcl-xL inhibits their anti-apoptotic function (Haldar, Basu
&Croce,1998;Basu&Haldar,2003;Upretietal.,2008;Terrano,Upreti&Chambers,2010).
Recent biochemical data now shows that cyclin B1/Cdk1 is the kinase that phosphorylates
Bcl-2 and Bcl-xL during prolongedmitosis after treatment with the microtubule inhibitor
vinblastine (Terrano, Upreti & Chambers, 2010). In addition, cyclin B1/Cdk1 can also
phosphorylateMcl-1toincreaseitsdegradationduringprolongedmitoticarrest(Harleyet
al.,2010;Wertzetal.,2011).Duringanormalmitoticcellcyclephase,cyclinB1/Cdk1only
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Therefore, it is likely that during Doc-mediated mitotic arrest, prolonged cyclin B1/Cdk1
activity hyperphosphorylates Bcl-2, Bcl-xL, and Mcl-1 to block their anti-apoptotic
function,whichislikelyimportantforincreasingcelldeath.
It is known that Doc chemotherapy alone is not enough to overcome the high levels of
Bcl-2, Bcl-xL, and Mcl-1 present in patients with CRPC (Karnak & Xu, 2010). A chemical
library identiﬁed ABT-737 as a small molecule that binds Bcl-2/Bcl-xL (but not Mcl-1)
with high aYnity to disrupt their interaction with Bax/Bak and enhance the apoptotic
signals, especially when combined with other chemotherapeutic drugs (Oltersdorf et al.,
2005; Tagscherer et al., 2008). The purpose of the present study is to determine whether
ABT-737 combined with Doc or a novel antimitotic ENMD-1198 (a more stable and
potentderivativeof2-methoxyestradiolwithclinicalpromise(LaValleeetal.,2008;Zhouet
al., 2011)) can overcome the high levels of Bcl-2/Bcl-xL/Mcl-1 in CRPC cells and enhance
apoptotic cell death. Our results show that ABT-737 enhances Doc and 1198-mediated
caspase-dependentapoptosisinsomePCacellsandthatthisenhancementisdependenton
expression of Bax and on cyclin B1/Cdk1-mediated phosphorylation of Bcl-2/Bcl-xL and
decreaseinMcl-1.
MATERIALS AND METHODS
Reagents
ABT-737 was obtained from Abbott Laboratories (Abbott Park, IL, USA), Doc from
Sanoﬁ-Aventis (Bridgewater, NJ, USA), and ENMD-1198 from EntreMed, Inc (Rockville,
MD,USA).Q-VDpan-caspaseinhibitorwaspurchasedfromR&DSystems(Minneapolis,
MN, USA); purvalanol A from A.G. Scientiﬁc (San Diego, CA, USA); Trypan blue (0.4%)
from Invitrogen (Grand Island, NY, USA); and Coomassie Blue from EMD Chemicals
(Billerica, MA, USA). All other reagents were purchased from Sigma-Aldrich (St. Louis,
MO,USA).
Cell culture
Human PCa cell lines LNCaP, DU145, and PC3 were obtained from the American
Type Culture Collection (Manassas, VA, USA) (van Bokhoven et al., 2003) and used
within 6 months of resuscitation of original cultures. All cells were maintained in
RPMI 1640 medium (Invitrogen) with 5% fetal bovine serum (Hyclone, Waltham,
MA), 100 U/ml penicillin, 100 g/ml streptomycin, and 0.25 g/ml amphotericin
(Invitrogen). Unlike LNCaP, LN-AI cells are able to grow for long-term in RPMI 1640
with5%charcoal-strippedfetalbovineserum(Hyclone)andarereferredtoasLN-AI/CSS
(Gomez,delasPozas&Perez-Stable,2006).
Western blot analysis
Preparation of total protein lysates and Western blot analysis was done as previously
described (Gomez, de las Pozas & Perez-Stable, 2006). The following antibodies were used:
Bcl-2 (N-19), Bax (N-20), Mcl-1 (S-19), cyclin B1 (GNS1), AIF (E-1), and horseradish
peroxidase-conjugated secondary antibody from Santa Cruz Biotechnology (Santa Cruz,
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cytochrome c (7H8.2C12), Smac (#612245) from BD Biosciences (San Diego, CA, USA);
cleaved PARP (9541), phospho-(Ser70) Bcl-2 (2827), CoxIV (#4844), Bid (#2002) from
Cell Signaling Technology (Danvers, MA, USA); phospho-(Ser62) Bcl-xl (30655) from
Abcam(Cambridge,MA,USA);andNoxa(114C307.1)fromNovusBiologicals(Littleton,
CO,USA).Afterimmunodetection,ourpreferenceforloadingcontrolswasforstainingof
total proteins transferred to the membrane with Coomassie Blue because drug treatments
oftenaVectthelevelsoftypicalhousekeepingproteinssuchasactinortubulin.
ABT-737 cell viability assay
LNCaP, DU145, and PC-3 cells were seeded in 96-well plates. The next day, fresh media
containing ABT-737 (1, 2.5, 5, 10 M), or control (0.1% DMSO) were added and
cells incubated for three days. The CellTiter Aqueous cell proliferation colorimetric
method from Promega (Madison, WI, USA) was used to determine cell viability, as per
manufacturer’s instructions. Cell viability was normalized against the vehicle control and
the data expressed asa percentage of control from three independent experimentsdone in
triplicate.
Drug treatments
PCa cells were cultured in media containing Doc (1 nM), 1198 (1 M), ABT-737 (1 M),
Doc or 1198 C ABT-737, Q-VD (10 M), purvalanol A (5 M), Doc or 1198 C Q-VD or
purvalanolA,orDMSO(0.1%)controlforvaryingtimes(24–72h).Inalltheexperiments,
ﬂoatingandtrypsinizedattachedcellswerepooledforfurtheranalysis.
Trypan blue exclusion assay
TreatedandcontrolPCacellswereharvested,resuspendedinPBS,diluted1:1in0.4%try-
pan blue, dead blue and live non-blue cells immediately counted using a hemacytometer,
andthe%deadbluecellsdeterminedfromatleastthreeindependentexperimentsdonein
duplicate.
Annexin-FITC/propidium iodide (PI) ﬂow cytometry
TreatedandcontrolPCacellswereresuspendedinbindingbuVerfollowedbytheaddition
of annexin V-FITC and PI (Annexin V Kit sc-4252 AK; Santa Cruz Biotechnology).
After 20 min, cells were analyzed by ﬂow cytometry using a Coulter XL ﬂow cytometer
and the percentage of annexinC cells determined using WinMDI version 2.8 from two
independentexperimentsdoneintriplicate.
Mitochondrial protein release assay
Treated and control PCa cells were resuspended in a buVer containing 100–200 M
digitonin, 20 mM Hepes, pH 7.5, 10 mM KCl, 1.5 mM MgCl, 1 mM EGTA, 1 mM EDTA,
1mMDTT,250mMsucrose,andproteaseinhibitors(Roche,Nutley,NJ)at50l/1 106
cells. After 5 min on ice, cells were centrifuged at 14k rpm 5 min and the supernatant used
for Western blot analysis. Digitonin is a detergent that preferentially permeabilizes plasma
membranecomparedtomitochondrialmembrane(Gottlieb&Granville,2002).
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hBaxC3-EGFP(plasmid19741;Addgene,Cambridge,MA,USA)(Nechushtanetal.,1999)
was digested with HindIII, blunt-ended with Klenow DNA polymerase, digested with
EcoRI, and the 0.6 kb Bax insert ligated into pBABE puro plasmid (BamH1-blunt/EcoRI)
using DNA ligase (New England Biolabs, Ipswich, MA, USA). Retrovirus production and
infection were done by transfecting HEK293T cells (American Type Culture Collection)
with pBABE/Bax or pBABE/EV (empty vector), pUMVC3, and pCVM-VSV-G with
FuGene HD (Roche), addition of ﬁltered (0.45 M) media after 48 h to DU145 and
LNCaP cells, and selection with puromycin (Invitrogen; 2 g/ml) for 1 week. Cell death
in DU145/Bax, DU145/EV, LNCaP/Bax, and LNCaP/EV cells treated with DMSO control
weresimilartoparentalcells(notshown).
Lentiviral transduction of LNCaP, DU145, and PC3 with shRNA
The shRNA design, lentivirus production, and infection were done as previously
described (Stewart et al., 2003). The following DNA oligonucleotides (Operon,
Huntsville, AL, USA) targeting Mcl-1, Bax, Bak, and cyclin B1 were cloned into
pLKO.1 lentivirus vector: shMcl-1 (M2): CCGGGCTGGAGA TTATCTCTCGGTACTC-
GAGTACCGAGAGATAATCTCCAGCTTTTTG; shMcl-1 (M3): CCGGGCTAAA-
CACTTGAAGACCATACTCGAGTATGGTCTTCAAGTGTTTAGC TTTTTG; shBax-1:
CCGGGCCGGAACTGATCAGAACCATCTCGAGATGGTTCTGATCAGTTCCGG
CTTTTTG (PC3); shBax-2: CCGGGCCTCAGGATGCGTCCACCAACTCGAGTTG-
GTGGACG CATCCTGAGGCTTTTTG (LNCaP); shBak-1: CCGGTGGTACGAA-
GATTCTTCAAATCTC GAGATTTGAAGAATCTTCGTACCATTTTTG (LNCaP);
shBak-3: CCGGATGAGTACTTCA CCAAGATTGCTCGAGCAATCTTGGTGAAG-
TACTCATTTTTTG (PC3); shCyclin B1-2: CCGG GCCAAATACCTGATGGAAC-
TACTCGAGTAGTTCCATCAGGTATTTGGCTTTTTG; and shCyclin B1-3: CCGGGC-
CATCCTAATTGACTGGCTACTCGAGTAGCCAGTCAATTAGGATG GCTTTTTG.
The control shRNA was targeted against green ﬂuorescent protein (GFP). For Mcl-1
knockdown inDU145/Bax andPC3/shCyclin B1 cells(puromycin resistant), shMcl-1and
shGFP oligonucleotides were cloned into pLKO.1/hygromycin plasmid and transduced
cells selected with 400 g/ml hygromycin (Invitrogen) for two weeks. Cell death in
DU145/shMcl-1,DU145/shGFP,DU145/Bax/shMcl-1,DU145/Bax/shGFP,LNCaP/shBax,
LNCaP/shBak, LNCaP/shGFP, PC3/shBax, PC3/shBak, PC3/shCyclin B1, PC3/shGFP,
PC3/shCyclin B1/shMcl-1, and PC3/shCyclin B1/shGFP cells treated with DMSO control
weresimilartoparentalcells(notshown).
Statistical analysis
Statistical diVerences between drug-treated and control PCa cells were determined by
two-tailedStudent’st-test(unequalvariance)withP < 0:05consideredsigniﬁcant.
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CRPC cells express high anti-apoptotic Bcl-2/Bcl-xL/Mcl-1 and low
or null pro-apoptotic Bax/Bak
Since ABT-737 is a Bcl-2/Bcl-xL antagonist that should promote the pro-apoptotic
function of Bax/Bak, we compared the protein levels of Bcl-2, Bcl-xL, Bax, and Bak in
LNCaP, DU145, and PC3 cells. LNCaP cells are androgen-dependent, contain wild-type
p53, and exhibit higher sensitivity to antimitotic-mediated apoptosis relative to DU145
andPC3,whicharecastration-resistantandp53mutatedornull(vanBokhovenetal.,2003;
Reiner et al., 2009). As expected, DU145 and PC3 expressed higher Bcl-2/Bcl-xL when
compared to LNCaP cells (Fig. 1A). Expression of Mcl-1, an anti-apoptotic member of
the Bcl-2 family that is not targeted by ABT-737 and is associated with chemoresistance to
ABT-737 treatment (van Delft et al., 2006; Chen et al., 2007; Lestini et al., 2009; Hauck et
al.,2009;Yeciesetal.,2010),washighestinDU145comparedtoPC3andLNCaPcells.The
proteinlevelsofpro-apoptoticBaxandBakwerelowerinCRPCcellscomparedtoLNCaP;
Bax is null in DU145 (Tang et al., 1998). These results suggest that the high anti-apoptotic
Bcl-2/Bcl-xL and low pro-apoptotic Bax/Bak protein environment present in CRPC cells
may beneﬁt from ABT-737 treatment in order to enhance apoptotic cell death. However,
DU145 cells were more resistant to ABT-737 as a single agent when compared to LNCaP
andPC3cells(Fig.1B).
ABT-737 enhances Doc/1198-mediated apoptosis in LNCaP and
PC3 but not in DU145 cells
CRPC cells such as DU145 and PC3 are more resistant to Doc treatment compared to
androgen-dependentcellssuchasLNCaPandcombinationswithotherdrugsoragentsare
requiredtoincreasetherapeuticeYcacy.Ourresultsshowedthatthecombinationof1nM
Doc or 1 M 1198 with a sub-cytotoxic dose of ABT-737 (1 M) signiﬁcantly increased
cell death and cleaved-PARP (measure of caspase activity) compared to the single agents
in LNCaP and PC3 but not in DU145 cells (Figs. 2A and 2B; Fig. S1A). Similar results
were obtained in LNCaP-AI/CSS, a CRPC variant of LNCaP that is more chemoresistant
(Fig. S1B). The pan-caspase inhibitor Q-VD (10 M) blocked DocC ABT-737-mediated
cell death and cleaved-PARP, indicating that increased caspase activity was required
(Figs.2Aand2B).
ABT-737 targets the mitochondria to initiate the intrinsic pathway of apoptosis by
increasing the release of mitochondrial proteins such as cytochrome c, which in turn
activates the caspase cascade (Chipuk et al., 2010). Our results indicated that ABT-737
enhanced Doc-mediated release of cytochrome c, Smac (blocks inhibitor of apoptosis
[IAP] family; LaCasse et al., 2008), and apoptosis-inducing factor (AIF; translocates to
nucleus to increase DNA fragmentation; Susin et al., 1999) from the mitochondria in
LNCaP and PC3 but not in DU145 cells (Fig. 2C; Fig. S2). In addition, there was less
cytoplasmic Bax protein in Doc C ABT-737 treated LNCaP and PC3 cells, likely as a
result of greater translocation of Bax to the mitochondria. Thus, ABT-737 enhancement
Parrondo et al. (2013), PeerJ, DOI 10.7717/peerj.144 6/22Figure 1 Bcl-2 family protein levels and sensitivity to ABT-737 in PCa cells. (A) Western blot analysis
showing that the levels of anti-apoptotic Bcl-2 and Bcl-xL proteins are higher in DU145 (D) and PC3 (P)
CRPC cells compared to androgen-dependent LNCaP (L) cells, whereas anti-apoptotic Mcl-1 is highest
in DU145. The levels of pro-apoptotic Bax and Bak are higher in LNCaP compared to DU145 (Bax
null) and PC3. After detection, Coomassie Blue stain of total protein transferred to the membrane is the
loading control. (B) Cell viability assay showing that LNCaP and PC3 are similarly sensitive to various
concentrations of ABT-737 (1–5 M; three days), whereas DU145 is more resistant.
of Doc-mediated pro-apoptotic protein release from the mitochondria correlates with
increasedapoptoticcelldeathinLNCaPandPC3butnotinDU145.
Bax expression but not Mcl-1 suppression sensitizes DU145 to
ABT-737 enhancement of Doc/1198-mediated apoptosis
We investigated the mechanisms by which DU145 cells are more resistant to ABT-737.
One possibility stems from the Bax null status of DU145 cells, which would indicate
that ABT-737 mediates its cytotoxicity via the Bax pathway. This is supported by a
previous ﬁnding indicating that transient transfection of Bax into DU145 cells increases
sensitivity to ABT-737 C TRAIL (Song, Kandasamy & Kraft, 2008). Another possibility
Parrondo et al. (2013), PeerJ, DOI 10.7717/peerj.144 7/22Figure 2 ABT-737 enhances Doc-mediated apoptotic cell death in LNCaP and PC3 but not in DU145
PCacells. (A) Trypan blue exclusion assay showing that the combination of 1 nM Doc C 1 M ABT-737
increases total cell death in LNCaP and PC3 but not in DU145 compared to Doc or ABT-737 alone
(, P < 2  10 4). LNCaP were treated for 48h and DU145 and PC3 for 72h. Pan-caspase inhibitor
Q-VD (10 M) blocks the Doc C ABT-737 increase in cell death. Western blot analysis showing that
Doc C ABT-737 increases cleaved-PARP (cP) levels in LNCaP and PC3 but not in DU145 compared to
Doc or ABT-737 alone. Q-VD blocks the Doc C ABT-737 increase in cP in all cells. (B) Flow cytometric
analysis showing higher annexin-FITC stained LNCaP and PC3 but not (continued on next page...)
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DU145 cells treated with Doc C ABT-737 compared to Doc or ABT-737 alone (, P < 210 5). Q-VD
blocks the Doc C ABT-737 increase in annexin C cells in LNCaP and PC3. (C) Mitochondrial protein
release assay and Western blot showing increased cytochrome c, Smac, AIF and decreased Bax in LNCaP
cells treated with Doc C ABT-737 compared to Doc or ABT-737 alone, and control. In DU145 cells,
cytochrome c, Smac, and AIF mitochondrial release were similar in Doc C ABT-737 as in Doc alone. Cox
IV protein is negative indicating no mitochondrial contamination whereas actin is the positive control.
C C for both LNCaP and DU145 is the lysate prepared from LNCaP cells using the standard method for
total proteins.
is that ABT-737 resistance of DU145 cells arises from elevated Mcl-1, which unlike
Bcl-2/Bcl-xL does not interact with ABT-737 and may therefore block the ability of
ABT-737 to increase apoptosis (van Delft et al., 2006; Chen et al., 2007; Lestini et al.,
2009; Hauck et al., 2009; Yecies et al., 2010). To address these possibilities, we isolated
DU145 cells stably expressing Bax and DU145 cells with stable Mcl-1 knockdown. Our
results showed that ABT-737 signiﬁcantly enhanced Doc/1198-mediated cell death in
DU145/Bax cells above Doc/1198 treatment alone (Figs. 3A and 3B). Similar results were
obtained in LNCaP/Bax cells (Fig. S3). In contrast, knockdown of Mcl-1 in DU145 or
DU145/Bax cells did not signiﬁcantly enhance Doc/1198 C ABT-737-mediated apoptotic
cell death (Fig. 3C; Fig. S4). These results indicate that DU145 cells are more resistant to
ABT-737 enhancement of antimitotic-mediated apoptosis because they are Bax null and
notbecausetheyexpresshighMcl-1.Incontrast,knockdownofMcl-1inLNCaPandPC3
cellsincreasedcelldeathandcl-PARP,conﬁrmingtheimportanceofMcl-1inresistanceto
Doc/1198CABT-737treatment(Fig.S5).
ABT-737-mediated enhancement of Doc/1198-induced apoptosis in
LNCaP is more dependent on Bax than Bak
ABT-737 inhibits the interactions of Bcl-2/Bax and Bcl-xL/Bak, thus allowing Bax and
Bak to induce MOMP and apoptosis (Oltersdorf et al., 2005; Tagscherer et al., 2008).
To further investigate the relative importance of Bax versus Bak in mediating ABT-737
enhancement of Doc/1198-mediated cell death in PCa cells, we isolated LNCaP and PC3
cells stably expressing either shBax or shBak. Results showed that knockdown of Bax
lowered Doc/1198 C ABT-737-mediated cell death and cleaved-PARP in both LNCaP
and PC3 cells compared to the negative control shGFP cells (Fig. 4A). Knockdown of Bak
also lowered Doc/1198 C ABT-737-induced cell death and cleaved-PARP in PC3 cells but
had no signiﬁcant eVects in LNCaP cells (Fig. 4B). These results suggest that ABT-737
enhancement of Doc/1198-mediated apoptosis in LNCaP cells is more dependent on Bax
thantoBakbutPC3cellsaredependentonbothBaxandBak.
Doc counteracts the ABT-737-mediated increase in Mcl-1
We examined whether Doc and Doc C ABT-737 had any eVects on the protein levels of
Bcl-2 family members in LNCaP and PC3 cells. Interestingly, Doc decreased and ABT-737
increased Mcl-1 but the combination of Doc C ABT-737 lowered Mcl-1 (Fig. 5). The
mechanismbywhichABT-737aloneincreasesMcl-1proteinisnotknownbutmayreﬂect
Parrondo et al. (2013), PeerJ, DOI 10.7717/peerj.144 9/22Figure 3 DU145 cells are resistant to ABT-737 because they are Bax null. (A) Trypan blue exclusion
assay showing that Doc C ABT-737 (DA) or 1198 C ABT-737 (98A) increases cell death at 72 h in
DU145/Bax compared to Doc (D) or 1198 (98) alone (, P < 0:008), whereas there is no eVect in
DU145/EV (empty vector) control cells. Western blot analysis showing that DA or 98A increases cP
in DU145/Bax cells compared to D or 98 alone, whereas there is no increase of cP in DU/EV cells.
Bax is expressed in DU145/Bax but not in DU145/EV cells. (B) Annexin-FITC/PI ﬂow cytometric
analysis showing higher annexinC and PIC cells in DA treated DU145/Bax compared to DU145/EV cells
(,P<110 6).(C)TrypanblueexclusionassayshowingthatDAor98Adoesnotsigniﬁcantlyincrease
cell death in DU145/shMcl-1 and DU145/shGFP control cells compared to D or 98 alone. Western blot
analysis showing no diVerence in the cP levels in DU145/shMcl-1 and DU145/shGFP control cells treated
with D, DA, 98, or 98A. Mcl-1 is expressed much higher in DU145/shGFP compared to DU145/shMcl-1
cells.
the observation that acquired resistance to ABT-737 involves increased Mcl-1 (Yecies et
al., 2010). There were no clear diVerences in the protein levels of Bcl-2, Bcl-xL, Bax, Bak,
Bid, and Noxa with the exception in LNCaP where there was less Bcl-2 (Doc, 24 h) and
Bak (Doc C ABT-737, 48 h). These results suggest that the Doc C ABT-737 enhancement
of apoptosis may depend upon the ability of Doc to counteract the ABT-737-mediated
increaseinMcl-1.
Parrondo et al. (2013), PeerJ, DOI 10.7717/peerj.144 10/22Figure 4 Bax suppression has a greater eVect on ABT-737-mediated Doc/1198-induced apoptotic cell
death than Bak suppression in LNCaP cells. (A) Trypan blue exclusion assay showing signiﬁcantly less
cell death in LNCaP/shBax and PC3/shBax cells treated with DA or 98A compared to shGFP (G) control
cells (, P < 0:02). Western blot analysis showing less cP and Bax in LNCaP/shBax and PC3/shBax cells
treated with DA or 98A compared to control cells. (B) Trypan blue exclusion assay showing less cell death
in PC3/shBak (, P < 6  10 4) but not in LNCaP/shBak cells treated with DA or 98A compared to
control cells. Western blot analysis showing less cP in PC3/shBak cells treated with D or 98 + A but little
diVerence in LNCaP/shBak cells compared to control cells. Bak is lower in LNCaP/shBak and PC3/shBak
cells compared to control cells.
Parrondo et al. (2013), PeerJ, DOI 10.7717/peerj.144 11/22Figure5 DoccounteractstheABT-737-mediatedincreaseinMcl-1protein. Western blot showing that
treatment of LNCaP and PC3 cells with 1 M ABT-737 (A) increases Mcl-1 but treatment with 1 nM
Doc (D) decreases Mcl-1. Combination of Doc C ABT-737 (DA) decreases Mcl-1. In LNCaP, there is less
Bcl-2 (D, 24 h) and Bak (DA, 48 h) but few diVerences in Bcl-xL, Bax, Bid, and Noxa. In PC3, there are
few diVerences in Bcl-2, Bcl-xL, Bax, Bak, Bid, and Noxa.
ABT-737-mediated enhancement of Doc-induced apoptosis is
dependent on cyclinB1/Cdk1-mediated phosphorylation of Bcl-
2/Bcl-xL and decrease of Mcl-1
Small molecule inhibitors of Cdk1 prevent Doc-mediated increase in cyclin B1/Cdk1
activity and blocks induction of apoptosis in CRPC cells (Perez-Stable, 2006; Gomez, de las
Pozas & Perez-Stable, 2006). We investigated whether cyclin B1/Cdk1-mediated increase
in Bcl-2/Bcl-xL phosphorylation and decrease in Mcl-1 is important for the ABT-737
enhancement of Doc-induced apoptosis. Treatment (Doc alone and Doc C ABT-737) of
LNCaP and PC3 but not DU145 cells increased phospho (P)-Bcl-2, whereas the levels
of P-Bcl-xL was similar in all three cell lines (Fig. S6). Addition of 5 M purvalanol A, a
speciﬁcinhibitorofcyclinB1/Cdk1activity(Grayetal.,1998)blockedDocCABT-737cell
death and the increase in P-Bcl-2/P-Bcl-xL in PC3 cells (Fig. 6A). However, purvalanol A
increasedMcl-1proteininDocCABT-737treatedPC3cells,suggestingthatthismayalso
playanimportantroleinblockingapoptoticcelldeath(Fig.6A).
To further determine whether the Doc-mediated increase in cyclin B1/Cdk1 activity,
P-Bcl-2/P-Bcl-xL, and decrease in Mcl-1 is important for ABT-737 C Doc cell death,
Parrondo et al. (2013), PeerJ, DOI 10.7717/peerj.144 12/22Figure 6 Inhibition of cyclinB1/Cdk1-mediated phosphorylation of Bcl-2/Bcl-xL blocks ABT-737
enhancementofDocinducedapoptosisinPC3cells.(A)Trypanblueexclusionassayshowingthat5M
purvalanol A (P) lowers DA cell death in PC3 cells (, P < 910 8). Western blot analysis showing that
P blocks the DA increase in cl-PARP, P-Bcl-2 and P-Bcl-xL, whereas there is no change in the total levels
of Bcl-2 and Bcl-xL; P treatment increases Mcl-1 in DA treated cells. Vertical line in cl-PARP indicates
sample from same blot not in sequence. (B) Trypan blue exclusion assay showing less cell death in DA
treated PC3/shCyclin B1-2 and -3 cells compared to PC3/shGFP control cells (, P < 410 5). Western
blot analysis showing less cyclin B1, cP, P-Bcl-2, P-Bcl-xL, and slightly greater Mcl-1 in PC3/shCyclin
B1-2 and -3 cells treated with DA compared to PC3/shGFP control cells.
we isolated PC3 cells stably expressing shCyclin B1. Results showed that knockdown of
cyclin B1 lowered Doc C ABT-737 cell death, cleaved-PARP, and P-Bcl-2/P-Bcl-xL in
PC3/shCyclinB1cellscomparedtoshGFPcontrolcells(Fig.6B).However,giventhatthere
is less cyclin B1 to mediate Cdk1 degradation of Mcl-1 by Doc, it is not surprising that
Mcl-1 levels are slightly higher in Doc C ABT-737 treated PC3/shCyclin B1 compared to
shGFP cells (Fig. 6B). We then isolated PC3/shCyclin B1 cells stably expressing shMcl-1
and the results showed that Doc C ABT-737 increased cell death (67%) nearly to the
levels of PC3/shMcl-1 cells (83%) (Fig. 7; Fig. S5B). Overall, these results suggest that the
Parrondo et al. (2013), PeerJ, DOI 10.7717/peerj.144 13/22Figure7 ABT-737enhancementofDoc-mediatedapoptosisismoredependentontheabilityofcyclin
B1/Cdk1 to decrease Mcl-1 than to phosphorylate Bcl-2/Bcl-xL. Trypan blue exclusion assay showing
greater cell death in DA treated (48 h) PC3/shCyclin B1/shMcl-1 (B1-2/M3, B1-3/M3) cells compared to
control PC3/shCyclin B1/shGFP (B1-2/G, B1-3/G) and PC3/shGFP (G) cells (, P <0:002). Western blot
analysis showing increased cl-PARP and decreased Mcl-1 in PC3/shCyclin B1/shMcl-1 compared control
shGFP cells after DA treatment (24 h). There is less cyclin B1, P-Bcl-1, and P-Bcl-xL in PC3/shCyclin
B1/shGFPorshMcl-1comparedtoPC3/shGFPcells,whereastherearenochangesintotalBcl-1orBcl-xL.
ABT-737 enhancement of Doc-mediated apoptosis is more dependent on the ability of
cyclinB1/Cdk1toincreasethedegradationofMcl-1thantophosphorylateBcl-2/Bcl-xL.
DISCUSSION
Progression of PCa to CRPC is often associated with overexpression of the anti-apoptotic
proteins Bcl-2, Bcl-xL, and Mcl-1, resulting in resistance to apoptosis and poor prognosis
(Karnak & Xu, 2010). Doc is an antimitotic drug approved for the treatment of CRPC
but the high levels of Bcl-2/Bcl-xL/Mcl-1 confers a block, resulting in less apoptosis
and reduced eYcacy. Here we report that the Bcl-2/Bcl-xL small molecule antagonist
ABT-737 can overcome this block and increase Doc and 1198 (new antimitotic)-induced
Parrondo et al. (2013), PeerJ, DOI 10.7717/peerj.144 14/22Figure 8 Schematic of how ABT-737 can sensitize Bax+ CRPC cells to Doc. Treatment of CRPC cells
such as PC3 with Doc deregulates cyclin B1/Cdk1 activity and increases phosphorylation of Bcl-2/Bcl-xL
and degradation of Mcl-1. However, the high levels of Bcl-2/Bcl-xL/Mcl-1 in CRPC cells presents a
block to apoptosis. Addition of ABT-737 disrupts the anti-apoptotic activity of Bcl-2/Bcl-xL and more
eVectivelyallowsDoctreatmenttobypasstheblockandincreaseapoptosis.CyclinB1/Cdk1hyperactivity
caused by Doc treatment also lowers Mcl-1, an ABT-737 resistance factor, to further increase apoptosis.
apoptosis in CRPC PC3 and LN-AI/CSS cells. However, another CRPC cell line, DU145,
is more resistant to ABT-737 due to the lack of the pro-apoptotic Bax protein and the
combination with Doc or 1198 did not further increase apoptosis. Our results also
indicate that the ABT-737 enhancement of Doc-mediated apoptosis in LNCaP and
PC3 cells is dependent upon the ability of Doc to constitutively activate cyclin B1/Cdk1
activity and hyperphosphorylate Bcl-2/Bcl-xL and decrease Mcl-1. Overall, these results
provide mechanistic insight into how ABT-737 can sensitize Bax expressing CRPC cells
to Doc/1198 treatment by overcoming the block in apoptosis due to the high levels of
Bcl-2/Bcl-xL/Mcl-1(Fig.8).
There is strong evidence that Bcl-2/Bcl-xL overexpression is important for CRPC
progression (Miyake, Monia & Gleave, 2000). Our results indicate that the commonly
utilized CRPC cell lines DU145 and PC3 express higher levels of Bcl2/Bcl-xL and lower
levels of Bax/Bak when compared to androgen-dependent LNCaP cells (Fig. 1A). Several
reports indicate that the eYcacy of ABT-737 positively correlates with Bcl-2 levels, i.e., the
higher the Bcl-2 the better the response to ABT-737 alone or in combination with other
chemotherapeutic agents (Del Gaizo Moore et al., 2008; Hann et al., 2008; Mason et al.,
2009; Oakes et al., 2012). This correlation does not appear to apply to PCa cell lines as
LNCaP has the lowest levels of Bcl-2 yet are as sensitive to ABT-737 as PC3 cells with the
highestlevelofBcl-2(Fig.1).
Parrondo et al. (2013), PeerJ, DOI 10.7717/peerj.144 15/22Numerous reports indicate that Mcl-1 overexpression in a variety of cancers can
mediate resistance to ABT-737 (van Delft et al., 2006; Chen et al., 2007; Lestini et al., 2009;
Hauck et al., 2009; Yecies et al., 2010). However, our results indicate that DU145 cells
are more resistant to ABT-737 as a single agent and in combination with Doc/1198 due
to the lack of Bax expression and not because they express the highest levels of Mcl-1.
In contrast, knockdown of Mcl-1 in Bax expressing LNCaP and PC3 cells enhances
sensitivity to Doc/1198 C ABT-737. It is possible that, in PCa cells, the complete loss of
Bax (as in DU145) is a more dominant mechanism for ABT-737 resistance compared
to overexpression of Mcl-1. In PC3, however, the Bax levels are much lower than in
LNCaP, yet both cells respond similarly to ABT-737, suggesting that only a low amount
of Bax protein is required. In PCa clinical biopsies, loss of Bax immunostaining relative
to normal non-cancer prostate epithelium is a useful biomarker for categorizing patient
risk and response to radiation therapy (Pollack et al., 2003; Khor et al., 2007). Therefore,
determining the percentage of Bax negative cells in human PCa specimens may provide a
usefulbiomarkerforidentifyingpatientsthatshouldrespondtoABT-737treatment.
During a normal mitotic cell cycle phase, cyclin B1/Cdk1 transiently phosphorylates
numerous substrates, including the anti-apoptotic proteins Bcl-2, Bcl-xL, and Mcl-1.
Antimitotic drugs such as Doc or 1198 can prevent the degradation of cyclin B1, resulting
in constitutively active Cdk1 activity and hyperphosphorylation of Bcl-2/Bcl-xL/Mcl-1.
Our results suggest that cyclinB1/Cdk1-mediated phosphorylation of Bcl-2/Bcl-xL is
important for the enhancement of apoptosis by the Doc C ABT-737 combination in
LNCaP and PC3 cells. This supports previous results that the antimitotic drug vinblastine
promotes apoptosis in HeLa cervical carcinoma cells by a similar mechanism (Terrano,
Upreti&Chambers,2010).Morerecently,thesensitivityofcancercellstoantimitoticdrugs
has been shown to have a dependence on the ability of cyclin B1/Cdk1 to phosphorylate
and increase the degradation of Mcl-1 in order to enhance apoptosis (Harley et al., 2010;
Wertz et al., 2011). Our results suggest that the antimitotic-mediated increase in cyclin
B1/Cdk1 activity and reduction of Mcl-1 protein counteracts the increase of Mcl-1 by
ABT-737, resulting in enhanced apoptosis. Antimitotic drugs or radiation treatment also
enhancecyclinB1/Cdk1phosphorylationofnumerousothersubstratesthatareimplicated
in either increasing or decreasing apoptosis (O’Connor et al., 2000; Konishi et al., 2002;
Berndtsson et al., 2005; Allan & Clarke, 2007; Andersen et al., 2009; Nantajit et al., 2010).
Overall, our results suggest that the cyclin B1/Cdk1-mediated hyperphosphorylation of
Bcl-2, Bcl-xL, and Mcl-1 is a major mechanism linking mitotic arrest to the induction of
apoptosisinPCacells.
Although our results do not address whether the Doc/1198 C ABT-737 combination
will be eVective in vivo, there is evidence in leukemia, and lung, prostate and breast cancer
to indicate that the antimitotic C ABT-737 combination should prove to be eVective in
animal models of PCa (Oakes et al., 2012; Shoemaker et al., 2006; Kang et al., 2007; Bray
et al., 2009). Navitoclax, previously known as ABT-263, is an orally bioavailable analog of
ABT-737withidenticalfunctionthatiscurrentlyinPhaseIItrialsforrefractorylymphoid
malignanciesandsolidtumorsandappearstobeapromisingagentforuseincombination
Parrondo et al. (2013), PeerJ, DOI 10.7717/peerj.144 16/22with Doc (Tse et al., 2008; Shi et al., 2011). Our results provide a strong mechanistic
rationale for combining targeted chemotherapy against Bcl2/Bcl-xL, as with navitoclax,
with the currently approved drug for CRPC Doc, which targets the destruction of Mcl-1,
a navitoclax resistance factor. With the addition of cabazitaxel to help in the treatment of
patients that develop Doc-resistance, it is also likely that the combination of cabazitaxel
andnavitoclaxwillfurtherimproveoverallsurvival(deBonoetal.,2010).
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